Ivo Abraham, PhD

Ivo Abraham is chief scientist of Matrix45 and professor of pharmacy, medicine, and clinical translational sciences at the University of Arizona, where he is associated with the Center for Health Outcomes and PharmacoEconomic Research. He has worked in biologic drugs since the late 1990s and in biosimilars since their introduction in the European marketplace – collaborating closely with Karen MacDonald, who is also his wife. On both the private and academic sides, his group published the first economic evaluations of biosimilars, a line of studies that continues to date. Building on large international observational studies on biological therapies that the Abraham-MacDonald tandem implemented in the late 1990s and early 2000s, they worked with Sandoz on the MONITOR-GCSF and MONITOR-CKD-5 studies that proved to be instrumental in the breakthrough of biosimilars in Europe. As biosimilars entered the US market, Matrix45 added studies in support of biosimilar adoption in the United States. More recently, Matrix45 has ventured into biosimilars in emerging markets, including low- and middle-income countries. He may be reached at cntr4biosimilars@matrix45.com.


Contributor: The Enemy of Your Enemy Should Be Your Friend – Why Biosimilars Companies Should Collaborate

May 09, 2022

Biosimilar manufacturers should consider working together to overcome some of the barriers that prevent biosimilars from entering the market and obtaining market share, according to Ivo Abraham, PhD, chief scientist of Matrix45 and a member of The Center for Biosimilars® Advisory Board.